Y Intercept Hong Kong Ltd Has $2.58 Million Stock Position in Quest Diagnostics Incorporated $DGX

Y Intercept Hong Kong Ltd cut its position in Quest Diagnostics Incorporated (NYSE:DGX) by 56.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,146 shares of the medical research company’s stock after selling 16,759 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Quest Diagnostics were worth $2,576,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DGX. Norges Bank bought a new position in Quest Diagnostics during the 4th quarter worth $229,522,000. Boston Partners boosted its position in Quest Diagnostics by 32.8% during the third quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock valued at $767,978,000 after acquiring an additional 997,033 shares during the last quarter. EdgePoint Investment Group Inc. boosted its position in Quest Diagnostics by 66,757.0% during the third quarter. EdgePoint Investment Group Inc. now owns 849,752 shares of the medical research company’s stock valued at $161,946,000 after acquiring an additional 848,481 shares during the last quarter. UBS Group AG grew its holdings in Quest Diagnostics by 67.8% during the 4th quarter. UBS Group AG now owns 1,114,451 shares of the medical research company’s stock worth $193,391,000 after acquiring an additional 450,161 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Quest Diagnostics by 36.3% in the 2nd quarter. Bank of America Corp DE now owns 1,599,602 shares of the medical research company’s stock valued at $287,337,000 after purchasing an additional 426,399 shares during the period. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Trading Down 0.5%

Quest Diagnostics stock opened at $212.41 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average price of $198.02 and a 200 day moving average price of $194.50. Quest Diagnostics Incorporated has a 52 week low of $164.65 and a 52 week high of $219.20. The company has a market capitalization of $23.51 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 2.54 and a beta of 0.58.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The firm had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same period in the prior year, the firm posted $1.94 earnings per share. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Sell-side analysts anticipate that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.

Quest Diagnostics Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th will be paid a $0.86 dividend. The ex-dividend date of this dividend is Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.6%. Quest Diagnostics’s payout ratio is currently 38.01%.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the sale, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at $25,708,601.22. The trade was a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on DGX shares. Truist Financial boosted their target price on Quest Diagnostics from $220.00 to $225.00 and gave the stock a “hold” rating in a research note on Wednesday, April 22nd. Evercore set a $225.00 target price on shares of Quest Diagnostics in a report on Tuesday, April 21st. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Robert W. Baird increased their price objective on shares of Quest Diagnostics from $224.00 to $229.00 and gave the company a “neutral” rating in a research report on Wednesday, April 22nd. Finally, Barclays raised their price target on Quest Diagnostics from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 22nd. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $216.58.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.